Research programme: abuse-resistant opioid analgesics - Pain Therapeutics/King PharmaceuticalsAlternative Names: Abuse-resistant oxymorphone
Latest Information Update: 16 Nov 2013
At a glance
- Originator DURECT Corporation
- Developer Pain Therapeutics; Pfizer
- Class Opioid peptides
- Mechanism of Action Opioid mu receptor agonists; Opioid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Suspended Pain